[133 Pages Report] The overall autoinjectors market is expected to grow from USD 25.84 billion in 2017 to USD 85.31 billion by 2023, at a CAGR of 24.2% from 2018 to 2023. Autoinjectors offer several advantages, such as reduces the chances of needlestick injuries, reduce needle phobia anxiety, maintain consistency regarding dose accuracy, and aid in better efficacy, which, in turn, help in the growth of the market. The autoinjectors market is expanding with the technological advancement and new design development. These autoinjectors are being used in many therapies such as rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Market Dynamics

Drivers

Growing prevalence of targeted therapies

Rising incidence of anaphylaxis

Increasing number of regulatory approvals

Availability of generic versions of autoinjectors

Restraints

Preference for alternative drug delivery modes

Opportunities

Patent expiry of biologics to drive the demand for biosimilars

Challenges

Development of autoinjectors for multiple drug viscosities

Lack of proper training for using autoinjectors

Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. Thus, the demand for autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. Among the various treatment options available for RA in the market, autoinjectors are the most advanced and convenient mode of tretment currently avialble in the market.

The following are the major objectives of the study.

To describe and forecast the autoinjectors market, in terms of value, by type, therapy, and end users

To describe and forecast the autoinjectors market, in terms of value, by regionAsia Pacific (APAC), Europe, North America, and Rest of the World (RoW) along with their respective countries

To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

To study the complete value chain of autoinjectors

To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the autoinjectors ecosystem

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders

To analyze strategic approaches such as product launches, acquisitions, contracts, agreements, and partnerships in the autoinjectors market

During this research study, major players operating in the autoinjectors market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

Major Market Developments

In April, 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.

In August, 2017, Amgen and Humana entered in to collaborative agreement for the development and research of medicines for multiple serious conditions including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer.

In May, 2018, Received EU approval for Repatha autoinjector. Similarly, the company has launched Enbrel auto-touch auto-injector in November, 2017.

Target Audience:

Autoinjectors manufacturing companies

Original equipment manufacturing companies

Suppliers and distributors of autoinjectors

Healthcare service providers

Teaching hospitals and academic medical centers

Health insurance players

Government bodies/municipal corporations

Regulatory bodies

Medical research institutes

Business research and consulting service providers

Venture capitalists

Market research and consulting firms

Report Scope:

The research report categorizes the autoinjectors market into the following segments and subsegments:

Geographic Analysis

Company Information

The autoinjectors market is expected to reach USD 85.31 billion by 2023 from USD 28.91 billion in 2018, at a CAGR of 24.2% from 2018 to 2023. The market is mainly driven by factors such as growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and availability of generic versions of autoinjectors.

Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug. Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases. They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.

On the basis of type, the autoinjectors market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.

On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2017. The large share of this segment is mainly attributed to the high prevalence of rheumatoid arthritis across the globe.

On the basis of end users, the autoinjectors market is segmented into home care settings and hospitals & clinics. The home care settings segment commanded the largest share of the autoinjectors market in 2017. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Autoinjectors applications in various therapeutic indications such as rheumatoid arthritis, diabetes, and anaphylaxis coupled with the growing prevalence of these targeted therapies drive the growth of autoinjectors market

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. Various treatment options are available for RA in the market, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid medicines or injections, conventional disease-modifying anti-rheumatic drugs (cDMARDs), and biological DMARDs (bDMARDs).Autoinjectors are the most convenient and effective mode of drug delivery option available for this therapeutic indication.

Diabetes

Diabetes mellitus, commonly known as diabetes, is a disease which arises from the insufficient production of insulin or the inability of the body to utilize insulin. The lack of insulin production or the inability of the body to utilize secreted insulin leads to the rise in blood glucose levels. Thus, in order to maintain healthy blood glucose levels, diabetes patients need a daily intake of insulin or Glucagon-like peptide-1 (GLP-1). GLP-1 therapy is delivered through pen devices as well as autoinjector devices. Currently, there are only two autoinjectors available for GLP-1 analogue, namely, Trulicity (dulaglutide) by Eli Lilly and Bydureon BCise (exenatide) by AstraZeneca.

Anaphylaxis

Anaphylaxis is a serious allergic or hypersensitivity reaction that can be life-threatening or fatal. It is characterized by rapidly developing, life-threatening problems involving the airway (pharyngeal or laryngeal edema) and/or breathing (bronchospasm with tachypnoea). Epinephrine autoinjectors are the most preferred mode of drug delivery and treatment option available for this therapy.

Critical questions the report answers:

Which of the therapeutic application market will dominate in future?

Which regions will provide the high growth opportunities?

Preference for alternative drug delivery modes such as oral diabetic agents, oral insulin, and epinephrine nasal sprays is a major factor restraining the growth of the market. Traditional injectables are invasive and painful modes of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes of drug delivery, such as oral, topical, and nasal routes. Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the autoinjectors market.